The complex contribution of chemokines to neuroinflammation: Switching from beneficial to detrimental effects

Annals of the New York Academy of Sciences

Volumn 1351, Issue 1, 2015, Pages 127-140

  Le Thuc, Ophélia ^a,b   Blondeau, Nicolas ^a,b   Nahon, Jean Louis ^a,b   Rovère, Carole ^a,b  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b CNRS   (France)

Author keywords

Central nervous system; Chemokines; CNS disorders; Neuroinflammation; Neuromodulation

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; FRACTALKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1; AUTACOID;

ALZHEIMER DISEASE; ARTICLE; BRAIN ISCHEMIA; BRAIN LEVEL; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NOMENCLATURE; PROTEIN STRUCTURE; BRAIN; CYTOLOGY; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IMMUNOLOGY; INFLAMMATION; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; BRAIN; CHEMOKINES; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; INFLAMMATION; INFLAMMATION MEDIATORS; NEUROIMMUNOMODULATION; RECEPTORS, CHEMOKINE; STROKE;

EID: 84941805980     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12855     Document Type: Article

References (79)

1. Banisadr, G., F. Queraud-Lesaux, M.C. Boutterin, et al. 2002. Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain. J. Neurochem. 81: 257-269.
2. van der Meer, P., A.M. Ulrich, F. Gonzalez-Scarano, et al. 2000. Immunohistochemical analysis of CCR2, CCR3, CCR5, and CXCR4 in the human brain: potential mechanisms for HIV dementia. Exp. Mol. Pathol. 69: 192-201.
3. Adler, M.W. & T.J. Rogers 2005. Are chemokines the third major system in the brain? J. Leukoc. Biol. 78: 1204-1209.
4. Rostene, W., M.A. Dansereau, D. Godefroy, et al. 2011. Neurochemokines: a menage a trois providing new insights on the functions of chemokines in the central nervous system. J. Neurochem. 118: 680-694.
5. Guyon, A., G. Banisadr, C. Rovere, et al. 2005. Complex effects of stromal cell-derived factor-1 alpha on melanin-concentrating hormone neuron excitability. Eur. J. Neurosci. 21: 701-710.
6. Guyon, A., C. Rovere, A. Cervantes, et al. 2005. Stromal cell-derived factor-1alpha directly modulates voltage-dependent currents of the action potential in mammalian neuronal cells. J. Neurochem. 93: 963-973.
7. Callewaere, C., G. Banisadr, M.G. Desarmenien, et al. 2006. The chemokine SDF-1/CXCL12 modulates the firing pattern of vasopressin neurons and counteracts induced vasopressin release through CXCR4. Proc. Natl. Acad. Sci. U.S.A. 103: 8221-8226.
8. Rostene, W., A. Guyon, L. Kular, et al. 2011. Chemokines and chemokine receptors: new actors in neuroendocrine regulations. Front. Neuroendocrinol. 32: 10-24.
9. Charo, I.F. & R.M. Ransohoff 2006. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354: 610-621.
10. Rostene, W., P. Kitabgi & S.M. Parsadaniantz 2007. Chemokines: a new class of neuromodulator? Nat. Rev. Neurosci. 8: 895-903.
11. Moser, B., M. Wolf, A. Walz, et al. 2004. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25: 75-84.
12. Zlotnik, A. & O. Yoshie 2012. The chemokine superfamily revisited. Immunity 36: 705-716.
13. Cardona, A.E., M. Li, L. Liu, et al. 2008. Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation. J. Leukoc. Biol. 84: 587-594.
14. Reaux-Le Goazigo, A., J. VanSteenwinckel, W. Rostene, et al. 2013. Current status of chemokines in the adult CNS. Prog. Neurobiol. 104: 67-92.
15. Apostolakis, S. & D. Spandidos 2013. Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway. Acta Pharmacol. Sin. 34: 1251-1256.
16. Sheridan, G.K. & K.J. Murphy 2013. Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. Open Biol. 3: 130181.
17. Hatori, K., A. Nagai, R. Heisel, et al. 2002. Fractalkine and fractalkine receptors in human neurons and glial cells. J. Neurosci. Res. 69: 418-426.
18. Hoshiko, M., I. Arnoux, E. Avignone, et al. 2012. Deficiency of the microglial receptor CX3CR1 impairs postnatal functional development of thalamocortical synapses in the barrel cortex. J. Neurosci. 32: 15106-15111.
19. Deshmane, S.L., S. Kremlev, S. Amini, et al. 2009. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29: 313-326.
20. Banisadr, G., R.D. Gosselin, P. Mechighel, et al. 2005. Highly regionalized neuronal expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) in rat brain: evidence for its colocalization with neurotransmitters and neuropeptides. J. Comp. Neurol. 489: 275-292.
21. Coughlan, C.M., C.M. McManus, M. Sharron, et al. 2000. Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons. Neuroscience 97: 591-600.
22. Meng, S.Z., A. Oka & S. Takashima 1999. Developmental expression of monocyte chemoattractant protein-1 in the human cerebellum and brainstem. Brain Dev. 21: 30-35.
23. Banisadr, G., D. Skrzydelski, P. Kitabgi, et al. 2003. Highly regionalized distribution of stromal cell-derived factor-1/CXCL12 in adult rat brain: constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons. Eur. J. Neurosci. 18: 1593-1606.
24. Reaux-Le Goazigo, A., C. Rivat, P. Kitabgi, et al. 2012. Cellular and subcellular localization of CXCL12 and CXCR4 in rat nociceptive structures: physiological relevance. Eur. J. Neurosci. 36: 2619-2631.
25. Shechter, R. & M. Schwartz 2013. CNS sterile injury: just another wound healing? Trends Mol. Med. 19: 135-143.
26. Dirnagl, U., C. Iadecola & M.A. Moskowitz 1999. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22: 391-397.
27. Jin, R., G. Yang & G. Li 2010. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J. Leukoc. Biol. 87: 779-789.
28. Soriano, S.G., L.S. Amaravadi, Y.F. Wang, et al. 2002. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J. Neuroimmunol. 125: 59-65.
29. Denes, A., S. Ferenczi, J. Halasz, et al. 2008. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J. Cereb. Blood Flow Metab. 28: 1707-1721.
30. Cipriani, R., P. Villa, G. Chece, et al. 2011. CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. J. Neurosci. 31: 16327-16335.
31. Tang, Z., Y. Gan, Q. Liu, et al. 2014. CX3CR1 deficiency suppresses activation and neurotoxicity of microglia/macrophage in experimental ischemic stroke. J. Neuroinflammation 11: 26.
32. Rosito, M., C. Lauro, G. Chece, et al. 2014. Trasmembrane chemokines CX3CL1 and CXCL16 drive interplay between neurons, microglia and astrocytes to counteract pMCAO and excitotoxic neuronal death. Front. Cell. Neurosci. 8: 193.
33. Pimentel-Coelho, P.M., J.P. Michaud & S. Rivest 2013. Evidence for a gender-specific protective role of innate immune receptors in a model of perinatal brain injury. J. Neurosci. 33: 11556-11572.
34. Donohue, M.M., K. Cain, D. Zierath, et al. 2012. Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke. Stroke 43: 2300-2306.
35. Blondeau, N., H. Plamondon, C. Richelme, et al. 2000. K(ATP) channel openers, adenosine agonists and epileptic preconditioning are stress signals inducing hippocampal neuroprotection. Neuroscience 100: 465-474.
36. Lauro, C., M. Catalano, E. Di Paolo, et al. 2014. Fractalkine/CX3CL1 engages different neuroprotective responses upon selective glutamate receptor overactivation. Front. Cell. Neurosci. 8: 472.
37. Limatola, C., C. Lauro, M. Catalano, et al. 2005. Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J. Neuroimmunol. 166: 19-28.
38. Wang, X. & G.Z. Feuerstein 1995. Induced expression of adhesion molecules following focal brain ischemia. J. Neurotrauma. 12: 825-832.
39. Che, X., W. Ye, L. Panga, et al. 2001. Monocyte chemoattractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. Brain Res. 902: 171-177.
40. Hughes, P.M., M.S. Botham, S. Frentzel, et al. 2002. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37: 314-327.
41. Dimitrijevic, O.B., S.M. Stamatovic, R.F. Keep, et al. 2006. Effects of the chemokine CCL2 on blood-brain barrier permeability during ischemia-reperfusion injury. J. Cereb. Blood Flow Metab. 26: 797-810.
42. Dimitrijevic, O.B., S.M. Stamatovic, R.F. Keep, et al. 2007. Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. Stroke 38: 1345-1353.
43. Schilling, M., J.K. Strecker, E.B. Ringelstein, et al. 2009. The role of CC chemokine receptor 2 on microglia activation and blood-borne cell recruitment after transient focal cerebral ischemia in mice. Brain Res. 1289: 79-84.
44. Allen, A.R., K. Eilertson, S. Sharma, et al. 2013. Effects of radiation combined injury on hippocampal function are modulated in mice deficient in chemokine receptor 2 (CCR2). Radiat. Res. 180: 78-88.
45. Strecker, J.K., J. Minnerup, K. Schutte-Nutgen, et al. 2013. Monocyte chemoattractant protein-1-deficiency results in altered blood-brain barrier breakdown after experimental stroke. Stroke 44: 2536-2544.
46. Liu, X.S., Z.G. Zhang, R.L. Zhang, et al. 2007. Chemokine ligand 2 (CCL2) induces migration and differentiation of subventricular zone cells after stroke. J. Neurosci. Res. 85: 2120-2125.
47. Gliem, M., A.K. Mausberg, J.I. Lee, et al. 2012. Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann. Neurol. 71: 743-752.
48. Huang, J., Y. Li, Y. Tang, et al. 2013. CXCR4 antagonist AMD3100 protects blood-brain barrier integrity and reduces inflammatory response after focal ischemia in mice. Stroke 44: 190-197.
49. Ruscher, K., E. Kuric, Y. Liu, et al. 2013. Inhibition of CXCL12 signaling attenuates the postischemic immune response and improves functional recovery after stroke. J. Cereb. Blood Flow Metab. 33: 1225-1234.
50. Li, Y., J. Huang, X. He, et al. 2014. Postacute stromal cell-derived factor-1alpha expression promotes neurovascular recovery in ischemic mice. Stroke 45: 1822-1829.
51. Mao, L., M. Huang, S.C. Chen, et al. 2014. Endogenous endothelial progenitor cells participate in neovascularization via CXCR4/SDF-1 axis and improve outcome after stroke. CNS Neurosci. Ther. 20: 460-468.
52. Shin, J.H., Y.M. Park, D.H. Kim, et al. 2014. Ischemic brain extract increases SDF-1 expression in astrocytes through the CXCR2/miR-223/miR-27b pathway. Biochim. Biophys. Acta 1839: 826-836.
53. Heppner, F.L., R.M. Ransohoff & B. Becher 2015. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16: 358-372.
54. Lee, S., N.H. Varvel, M.E. Konerth, et al. 2010. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am. J. Pathol. 177: 2549-2562.
55. Cho, S.H., B. Sun, Y. Zhou, et al. 2011. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 286: 32713-32722.
56. Lee, S., G. Xu, T.R. Jay, et al. 2014. Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. J. Neurosci. 34: 12538-12546.
57. Nash, K.R., D.C. Lee, J.B. Hunt, Jr., et al. 2013. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol. Aging 34: 1540-1548.
58. Kim, T.S., H.K. Lim, J.Y. Lee, et al. 2008. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 436: 196-200.
59. Strobel, S., E. Grunblatt, P. Riederer, et al. 2015. Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPARγ. J. Neural Transm. 122: 1069-1076.
60. Ishizuka, K., T. Kimura, R. Igata-yi, et al. 1997. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin. Neurosci. 51: 135-138.
61. Grammas, P. & R. Ovase 2001. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol. Aging 22: 837-842.
62. + monocytes: the hidden side of Alzheimer's disease. J. Mol. Cell. Biol. 5: 284-293.
63. Smits, H.A., A. Rijsmus, J.H. vanLoon, et al. 2002. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J. Neuroimmunol. 127: 160-168.
64. Meda, L., S. Bernasconi, C. Bonaiuto, et al. 1996. Beta-amyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes and microglial cells. J. Immunol. 157: 1213-1218.
65. El Khoury, J.B., K.J. Moore, T.K. Means, et al. 2003. CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 197: 1657-1666.
66. Vukic, V., D. Callaghan, D. Walker, et al. 2009. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol. Dis. 34: 95-106.
67. Berger, O., X. Gan, C. Gujuluva, et al. 1999. CXC and CC chemokine receptors on coronary and brain endothelia. Mol. Med. 5: 795-805.
68. Roberts, T.K., E.A. Eugenin, L. Lopez, et al. 2012. CCL2 disrupts the adherens junction: implications for neuroinflammation. Lab. Invest. 92: 1213-1233.
69. Galimberti, D., C. Fenoglio, C. Lovati, et al. 2006. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol. Aging 27: 1763-1768.
70. Galimberti, D., N. Schoonenboom, P. Scheltens, et al. 2006. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch. Neurol. 63: 538-543.
71. Kiyota, T., H.E. Gendelman, R.A. Weir, et al. 2013. CCL2 affects beta-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiol. Aging 34: 1060-1068.
72. El Khoury, J., M. Toft, S.E. Hickman, et al. 2007. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13: 432-438.
73. Weeraratna, A.T., A. Kalehua, I. Deleon, et al. 2007. Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues. Exp. Cell Res. 313: 450-461.
74. Parachikova, A. & C.W. Cotman 2007. Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease. Neurobiol. Dis. 28: 143-153.
75. Laske, C., K. Stellos, E. Stransky, et al. 2008. Decreased plasma and cerebrospinal fluid levels of stem cell factor in patients with early Alzheimer's disease. J. Alzheimers Dis. 15: 451-460.
76. Raman, D., S.Z. Milatovic, D. Milatovic, et al. 2011. Chemokines, macrophage inflammatory protein-2 and stromal cell-derived factor-1alpha, suppress amyloid beta-induced neurotoxicity. Toxicol. Appl. Pharmacol. 256: 300-313.
77. Wang, Q., Y. Xu, J.C. Chen, et al. 2012. Stromal cell-derived factor 1alpha decreases beta-amyloid deposition in Alzheimer's disease mouse model. Brain Res. 1459: 15-26.
78. Guyon, A., D. Skrzydelski, I. DeGiry, et al. 2009. Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release. Neuroscience 162: 1072-1080.
79. Le Thuc, O., N. Blondeau, W. Rostène, et al. 2013. The chemokine MCP1 mediates inflammation-induced anorexia through its action on hypothalamic MCH neurons. Presented at 11ème Colloque de la Société des Neurosciences, Lyon, France, 21-24 May 2014.